4 active not recruiting, 2 completed, 1 unknown. 5 Phase 2, 2 Phase 1, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 4, Completed 1 |
| Phase 1 | 2 | Active not recruiting 2 |
| Not applicable | 1 | Completed 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Radium-223 chloride: new trials by email Literature Review of Radium-223 chloride trials Research Report on Radium-223 chloride
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy Avelumab, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 90 | 2020-10-14 | 2026-10-07 |
| Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones Biospecimen Collection, Bone Scan, Computed Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 70 | 2020-08-04 | 2026-09-18 |
| Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study Biospecimen Collection, Bone Scan, Cabozantinib S-malate - Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 98 | 2020-07-29 | 2026-09-28 |
| Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis Biopsy Procedure, Biospecimen Collection, Computed Tomography - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 132 | 2019-02-04 | 2026-09-09 |
| Rhenium-188-HEDP vs. Radium-223-chloride in Patients With Advanced Prostate Cancer Refractory to Hormonal Therapy Radium-223 chloride, Rhenium-188-HEDP - Prostate Cancer Metastatic to Bone | Phase 3 | Unknown | Amsterdam UMC, location VUmc | 402 | 2018-05-16 | 2020-11-17 |
| Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer Ra-223 dichloride, Denosumab, Hormone Therapy - Breast Cancer | Phase 2 | Completed | M.D. Anderson Cancer Center | 45 | 2015-02-11 | 2021-10-07 |
| Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases Alpharadin - Prostate Cancer | Not applicable | Completed | M.D. Anderson Cancer Center | 27 | 2014-09-19 | 2022-02-17 |
Prostatic Neoplasms (4) · Breast Neoplasms (1) · Carcinoma, Renal Cell (1) · Lymphatic Metastasis (1)
National Cancer Institute (NCI) (4) · M.D. Anderson Cancer Center (2) · Amsterdam UMC, location VUmc (1)
United States (6) · Netherlands (1)
Rana R McKay (2) · John Araujo, MD,PHD (1) · Naoto Ueno, MD, PHD (1) · Russell K Pachynski (1) · Scott M Glaser (1)
PMID 31849202, PMID 33604999, PMID 41454189, PMID 42507969
UM1CA186689 (2), U10CA180821 (1), UM1CA186644 (1), UM1CA186704 (1), UM1CA186716 (1)